PRME shows a high-asymmetry technical recovery with large modeled upside, but extreme cash burn keeps quality well below an acceptable floor, and elevated options positioning alongside thin analyst coverage adds further uncertainty to the setup.
Thesis pillars
- High Asymmetry Recovery Setup→Stable
- Extreme Cash Burn Quality Concern→Stable
- Analyst Upside With Light Coverage→Stable
- +1 more pillar — see the Why tab for full reasoning
Prime Medicine, Inc. (PRME) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.00: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality.
Prime Medicine develops genetic medicines using Prime Editing, a gene-editing technology that rewrites DNA without double-stranded breaks, led by PM577 for Wilson Disease and PM647 for alpha-1 antitrypsin deficiency, plus an ex vivo T-cell collaboration with Bristol-Myers... Read more
Sell if holding. Engine safety override at $4.00: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 82. Score 4.1/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 32d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Prime Medicine, Inc.
About Prime Medicine, Inc.
Prime Medicine's lead in vivo program, PM577 for Wilson Disease, targets the H1069Q ATP7B mutation using Prime Editing — a gene-editing technology designed to rewrite DNA without double-stranded breaks — with an IND/CTA filing planned for the first half of 2026. The company's most clinically advanced asset, the ex vivo program PM359 for chronic granulomatous disease, has already restored NADPH oxidase activity in two treated patients.
Prime Medicine has no approved products and earns revenue solely through collaboration and grant funding: a September 2024 license agreement with Bristol-Myers Squibb subsidiary Juno Therapeutics paid a $55 million upfront fee plus a $55 million equity investment for exclusive rights to apply Prime Editing to ex vivo T-cell engineering in oncology and immunology, with up to $3.5 billion in potential milestones and royalties on any future sales. A separate 2024 agreement with the Cystic Fibrosis Foundation provides up to $15 million to fund CF-directed Prime Editing research. Internally, the company is prioritizing liver-directed in vivo programs — Wilson Disease and alpha-1 antitrypsin deficiency — delivered via a shared lipid-nanoparticle platform that lets the same editor and delivery components carry over across mutation-specific programs, an approach management says can shorten IND-enabling toxicology and CMC work for follow-on candidates.
Show full overview
Prime Medicine's story currently rests on validating Prime Editing itself, not a single pivotal readout: the 10-K discloses that its $177.7 million in cash and investments as of December 31, 2025 will not fund operations for more than one year beyond the filing date, and management has determined there is substantial doubt about the company's ability to continue as a going concern absent additional financing. That risk sits beside a favorable signal — durable NADPH oxidase restoration in the two CGD patients dosed with PM359 — so the catalyst investors are watching is less a trial result than whether Prime Medicine secures financing or a partnership before its runway expires.
See also: Healthcare · Biotechnology
From Prime Medicine, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-07Recent Developments — Prime Medicine, Inc.
Latest news
- NEWS Iridium Communications, FuelCell Energy, Rocket Lab And Other Big Stocks Moving Higher On Monday — benzinga Jun 29, 2026 neutral
Generated 2026-07-07T13:21:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-16Item 5.02LOWBoard appointed Svetlana Makhni as CFO and principal financial officer effective April 16, 2026. Prior CFO departure/successor context not cited in fetched excerpt; routine officer appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
6 floor-breakers·1 ceiling hit
Revenue shrinking — -41.1% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Volatile — 8.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.00: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 82. Prior stop was $3.71. Score 4.1/10, moderate confidence.
Take-profit target: $6.10 (+52.9% upside). Prior stop was $3.71. Stop-loss: $3.71.
Quality below floor (2.0 < 4.0).
Prime Medicine, Inc. trades at a P/E of N/A (forward -4.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
19 analysts cover PRME with a consensus score of 4.1/5. Average price target: $7.
What does Prime Medicine, Inc. do?Prime Medicine develops genetic medicines using Prime Editing, a gene-editing technology that rewrites DNA without...
Prime Medicine develops genetic medicines using Prime Editing, a gene-editing technology that rewrites DNA without double-stranded breaks, led by PM577 for Wilson Disease and PM647 for alpha-1 antitrypsin deficiency, plus an ex vivo T-cell collaboration with Bristol-Myers Squibb. The pre-revenue company held $177.7 million in cash and investments as of December 31, 2025, and received a $55 million upfront payment from BMS with up to $3.5 billion in potential milestones.